Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/139309PSEUDOMONAS INACTIVATED VACCINE "PSEUDOPRIMAVAC" AGAINST PSEUDOMONAS
WO 02.07.2020
Int.Class A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
Appl.No PCT/UA2019/000163 Applicant MARKOV, Ihor Semenovych Inventor MARKOV, Ihor Semenovych
The inventions relate to medical microbiology and the pharmaceutical industry, in particular to vaccine preparations, namely vaccines against Pseudomonas infection, methods for the production of said vaccines, and methods of treatment and prophylaxis, and can be used for therapeutic and prophylactic purposes in acute and chronic bacterial diseases of Pseudomonas etiology. A vaccine comprises at least 12 clinical pathogenic strains of four types of bacteria of genus Pseudomonas, namely: 9 of Pseudomonas aeruginosa, 1 of Pseudomonas maltophilia, 1 of Pseudomonas alcaligenes and 1 of Pseudomonas stutzeri, isolated in various acute and chronic inflammatory diseases of bacterial etiology. The inventions increase the immunogenic effect of the vaccine, strengthen the immunological and clinical effect after vaccination without allergic reactions and provide a wide spectrum of application.
2.WO/2020/135201ANTIBODY AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/126495 Applicant SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Inventor TIAN, Haijun
The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
3.WO/2020/135335MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2019/127433 Applicant GENERON (SHANGHAI) CORPORATION LTD. Inventor HUANG, Zhihua
Provided are multispecific antigen binding proteins (MSAPs) that specifically bind to CD3 and CD19. Further provided are uses of the MSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSAPs.
4.WO/2020/135415USE OF ANTI-PD-L1 MONOCLONAL ANTIBODY FOR TREATMENT OF CANCER
WO 02.07.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2019/127891 Applicant CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Inventor ZHANG, Xiquan
The present application provides use of an anti-PD-L1 monoclonal antibody for treatment of cancer, comprising administering to a subject a therapeutically effective amount of an inhibitor of the interaction between a PD-1 receptor and a ligand PD-L1 thereof, wherein the inhibitor is an anti-PD-L1 monoclonal antibody.
5.WO/2020/136603USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING ATHEROSCLEROSIS
WO 02.07.2020
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/IB2019/061377 Applicant NEURACLE SCIENCE CO., LTD. Inventor KIM, Bongcheol
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
6.WO/2020/136060A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/086072 Applicant F. HOFFMANN-LA ROCHE AG Inventor KNOETGEN, Hendrik
The present invention relates to a peptide-MHC-I-antibody fusion protein for use as a therapeutic medicament administered to a patient, wherein a cellular cytotoxic immune response towards the virus-derived peptide has been amplified in the patient. The therapeutic medicament may be used in a kit of parts and administered in combination with an amplifying medicament and optionally an inducing medicament. The inducing medicament and the amplifying medicament may be for use in a method of making a patient susceptible for a treatment with the peptide-MHC-I-antibody fusion protein.The medicament(s) may be used for the treatment of diseases, such as cancer or a viral infection.
7.WO/2020/136657POLYMERIC NANOVACCINES AND USES THEREOF
WO 02.07.2020
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No PCT/IL2019/051420 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor SATCHI-FAINARO, Ronit
A polymeric nanoparticle is disclosed which comprises: (i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle: (ii) at least one adjuvant, and (iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle. Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.
8.WO/2020/138489NOVEL ANTI-CCR8 ANTIBODY
WO 02.07.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2019/051603 Applicant SHIONOGI & CO., LTD. Inventor KODAMA Mai
Disclosed is a novel anti-CCR8 antibody. The antibody may be used for treating or preventing cancers or the like.
9.WO/2020/140123NOVEL METHIONINE CONTAINING ANTIBODIES FOR CONJUGATION OF AGENTS
WO 02.07.2020
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No PCT/US2019/068985 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor WELLS, James
Provided herein are novel antibody-agent conjugates formed by the introduction of methionine residues to antibody scaffold light or heavy chains at select positions, followed by conjugation of the agent to the methionine, for example, by oxaziridine chemistries. Methionine substitutions at the targeted positions enable highly efficient functionalization to form very stable conjugates, including conjugates suitable for in vivo use. The positions were identified for the trastuzumab and other related scaffolds which can be engineered for affinity to any target antigen. The conjugates include ADCs and detections agents. Also disclosed are novel oxaziridine reagents for conjugation to methionines in proteins.
10.WO/2020/135471MONOCLONAL ANTIBODY AGAINST HUMAN INTERLEUKIN-4 RECEPTOR ALPHA AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/128156 Applicant QYUNS THERAPEUTICS CO., LTD. Inventor QIU, Jiwan
Provided are antibodies and fragments against human interleukin-4 receptor alpha (hIL-4Rα) and uses thereof. The antibodies and fragments preferably have heavy chain complementary determining regions as set forth in SEQ ID NOs: 1-3 or 14-16 and light chain complementary determining regions as set forth in SEQ ID NOs: 4-6 or 17-19.